Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis

[1]  M. Levy,et al.  Two‐year observational study of deferiprone in superficial siderosis , 2017, CNS neuroscience & therapeutics.

[2]  S. Farmer,et al.  Infratentorial superficial siderosis: Classification, diagnostic criteria, and rational investigation pathway , 2017, Annals of neurology.

[3]  J. Palmblad,et al.  Deferiprone‐induced agranulocytosis: 20 years of clinical observations , 2016, American journal of hematology.

[4]  M. Callaghan,et al.  Agranulocytosis with deferiprone treatment of superficial siderosis , 2013, BMJ Case Reports.

[5]  L. Della Corte,et al.  Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration , 2011, Journal of Neural Transmission.

[6]  R. Llinas,et al.  Superficial siderosis: a case report and review of the literature , 2007, Nature Clinical Practice Neurology.

[7]  J. Dichgans,et al.  Superficial siderosis of the central nervous system , 1991, European Archives of Psychiatry and Clinical Neuroscience.

[8]  A. Fergus,et al.  Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. , 1997, Neurosurgery.

[9]  C. Cooper,et al.  The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase* , 1996, The Journal of Biological Chemistry.

[10]  J. Stevens,et al.  REVIEW ARTICLESuperficial siderosis of the central nervous system , 1995 .

[11]  R. Abeysinghe,et al.  Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. , 1991, Blood.